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Abstract
Background: As with most medications, benzodiazepine and similar sedative hypnotics (BDZ/
SSH) can produce both beneficial and adverse effects. Pharmacoepidemiological studies have been
limited in their capacity to evaluate the relationship between these medications and psychiatric
diagnoses in non-clinical populations. The objective of this study was to provide a description of
the pattern of use of BDZ/SSH medications in relation to both demographic and diagnostic data in
a community population.
Methods: The source of data for this study was the Canadian Community Health Survey (CCHS
1.2), also known as the Canadian National Study of Mental Health and Well-being. This study was
based on a nationally representative sample that included over 35 thousand subjects with a
response rate of 77%. The survey interview included the latest version of the Composite
International Diagnostic Interview (CIDI), which was developed for the World Health
Organization's WHO Mental Health 2000 project. Current medication use was also recorded.
Results: As expected, BDZ/SSH use was more common in women than in men (4.2%, 95% CI 3.9
to 4.6 vs. 2.5%, 95% CI 2.2 to 2.8) and its frequency increased with age, 8.5% (95% CI 7.7 to 9.4)
of those over the age of 65 compared to 2.4% (95% CI 2.2 to 2.7) of those aged 18 to 64 years.
These medications were more frequently used in subjects with low levels of education (4.8%, 95%
CI% 4.3 to 5.2) vs. high levels of education (2.4%, 95% CI 2.1 to 2.6) and low personal incomes
(5.7%, 95% CI 5.2 to 6.3) vs. high personal incomes (2.3%, 95% CI 2.0 to 2.6). BDZ/SSH use was
strongly associated with the presence of mood or anxiety disorders, but not with substance use
disorders. Demographic differences persisted after statistical adjustment for diagnosis.
Conclusion: The observation that benzodiazepine use is more frequent in women, increases with
age and is higher in low income and education groups supports previous findings. These results help
to confirm that these differences are not accounted for by psychiatric diagnoses.
Background
Benzodiazepines are in their fifth decade of use and
remain among the most frequently prescribed drugs.
These medications can be beneficial in the short-term
management of diverse symptoms, most notably anxiety,
insomnia and agitation. However, they also have adverse
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effects which can be fatal, particularly with long-term use
and use in the elderly, where epidemiological studies have
linked benzodiazepine exposure to motor vehicle acci-
dents [1], hip fractures [2,3] cognitive problems and self
care limitations [4]. The increased risk of injury due to
traffic accidents may not be restricted to the elderly age
group [5-7]. Benzodiazepine use can lead to dependence
[8,9], and can contribute to overdose fatalities [10].
Zopiclone and zaleplon are non-benzodiazepine sedative
hypnotics, which nevertheless share many pharmacologi-
cal properties with benzodiazepines, potentially includ-
ing many of their adverse effects and risks [11-15]. In this
paper, benzodiazepines and zopiclone are grouped
together as benzodiazepines and similar sedative hypnot-
ics (BDZ/SSH). At the time of the study zaleplon had only
been recently approved in Canada and this medication
had not yet been assigned a unique identifying code, it
was therefore not included in the analysis. Another drug,
zolpidem was not included, as it had not been approved
for use in Canada when this study was conducted.
An increased frequency of BDZ/SSH use with age has been
reported [16-18], a phenomenon that cannot be due to
confounding by mood or anxiety disorder status, since the
prevalence of these disorders declines with age [19,20].
However, these same studies have reported a higher fre-
quency of use in women, which could result from a higher
prevalence of mood and anxiety disorders in women.
Similarly, if subject characteristics indicative of low socio-
economic status (e.g. lower levels of education, low
income) and unmarried status are associated with mood
and anxiety disorders, these variables could appear to be
associated with BDZ/SSH use because of confounding
with mood or anxiety disorders. The only recent study to
evaluate mood and anxiety disorder status in relation to
current BDZ/SSH use in a general population sample was
a French study [17] that included a brief diagnostic inter-
view, the Mini International Neuropsychiatric Interview
(MINI) [21]. The authors reported that the association of
BDZ/SSH use with increasing age and female sex persisted
after adjustment for mood and/or anxiety disorder status.
The objective of this analysis was to extend these observa-
tions using data from a 2002 Canadian survey called the
Canadian Community Health Survey 1.2 (CCHS 1.2), or
the Canadian National Survey of Mental Health and Well-
being. This study included a more detailed diagnostic
assessment interview than the MINI instrument, the
WHO Mental Health Version of the Composite Interna-
tional Diagnostic Interview (WMH-CIDI) [22].
Methods
The CCHS 1.2 was a cross-sectional survey conducted by
Statistics Canada (the Canadian Government's statistical
agency) to collect information on mental health status,
mental health care utilization and mental health determi-
nants. The mental disorders investigated included depres-
sion, mania, panic disorder, social phobia, agoraphobia,
alcohol dependence and illicit drug dependence. These
were determined using a version of the CIDI developed
for the World Mental Health 2000 Survey (WMH2000)
[22]. An exception was alcohol dependence, for which the
CCHS 1.2 used a CIDI-Short Form (CIDI-SF) [23]. Both
the WMH2000 CIDI and CIDI-SF interviews applied defi-
nitions from the Diagnostic and Statistical Manual of
Mental Disorders, Fourth Edition (DSM-IV) [8].
The WMH2000 version of the CIDI generates past year
and lifetime diagnoses of psychiatric disorders. During
the interview, which was usually conducted in their
homes, study participants were asked to collect all of their
medication containers for any medication taken in the
preceding two days. These were subsequently coded for
analysis using the WHO Anatomic Therapeutic Classifica-
tion (ATC) system. Data were collected between May
2002 and December 2002.
Education was categorized at two levels, subjects with less
than high school education and subjects having graduated
from high school, with or without additional post-sec-
ondary schooling. Income was designated as "low" using
Statistics Canada formulas that account for total family
income, adjusted for family size. The "lowest" and "low
middle" categories were aggregated for analysis.
The analysis presented here consisted of tabulation and
logistic regression analyses. Design effects were accounted
for by the use of sampling weights and a bootstrap proce-
dure for variance estimation. All analyses were conducted
using SAS statistical software [24]. The study received
approval from the University of Calgary Conjoint Medical
Ethics Review Board.
Results
The response rate for the CCHS 1.2 was 77%. For this
analysis, the total sample (n = 36,984) was restricted to
include 35,236 subjects 18 years old or older. The
restricted sample comprised 15,889 (45.1%) men and
19,347 (54.9%) women. The overall (weighted) fre-
quency of use of BDZ/SSH was 3.4% (95% CI 3.1 – 3.6).
Table 1 shows the frequency of benzodiazepine use in
relation to age, sex, marital status, income and education.
The frequency of use, as shown in Table 1, was higher in
women, those over the age of 65, those with low educa-
tion, low income and those who were single, separated,
divorced or widowed.
Frequency estimates stratified for disorder status are pre-
sented in Table 2. After stratifying for the presence of anx-Population Health Metrics 2006, 4:15 http://www.pophealthmetrics.com/content/4/1/15
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iety or mood disorders, the pattern of an increased
frequency of benzodiazepine and similar sedative-hyp-
notic use in women, unmarried subjects, and those with
low income and education continued. As expected, anxi-
ety and mood disorders were themselves strongly associ-
ated with benzodiazepine and similar sedative-hypnotic
use.
Logistic regression models predicting benzodiazepine or
similar sedative-hypnotic use were generated using sex,
marital status, income or education, the presence of an
anxiety or mood disorder and the corresponding two-way
interaction term as predictor variables. Wald tests identi-
fied no evidence of interaction between these variables
and anxiety or mood disorders in the models containing
sex, marital status or education. In the model for income,
however, the presence of an anxiety or mood disorder and
low income interacted according to the Wald test (z = 4.7,
p = 0.03), indicating that BDZ/SSH use was more strongly
associated with (low) income in subjects without a mood
or anxiety disorder (OR 2.7) than in subjects with a mood
or anxiety disorder (OR 1.8). After adjustment for the
presence of an anxiety or mood disorder, the odds ratio
for (female) sex was 1.6 (95% CI 1.3 – 1.8). For (unmar-
ried) marital status, the odds ratio was 1.4 (95% CI 1.2 –
Table 2: Frequency (%) of Benzodiazepine and Similar Sedative-Hypnotic Use in Demographic Categories, Stratified by the Presence 
of an Anxiety or Mood Disorder
%
With Anxiety/Mood Disorder Without Anxiety/Mood Disorder
Sex
• Men 9.4 2.0
• Women 11.0 3.3
Marital Status
• Married or Common-law 10.0 2.3
• Single, Separated, Divorced, Widowed (Unmarried) 10.9 3.4
Income
• High Income 8.5 1.8
• Low Income 14.1 4.6
Education
• High Education 8.0 1.8
• Low Education 13.9 3.8
Table 1: Frequency (%) of Benzodiazepine and Similar Sedative-Hypnotic Use, by Demographic Variables
Demographic Variables % 95% C.I.
Sex
• Men 2.5 2.2 – 2.8
• Women 4.2 3.9 – 4.6
Age
• 18 to 64 years 2.4 2.2 – 2.7
• 65 years and over 8.5 7.7 – 9.4
Marital Status
• Married or Common-law 2.8 2.5 – 3.1
• Single, Separated, Divorced, Widowed 4.4 4.0 – 4.8
Income
• High Income 2.3 2.0 – 2.6
• Low Income 5.7 5.2 – 6.3
Education
• High Education 2.4 2.1 – 2.6
• Low Education 4.8 4.3 – 5.2Population Health Metrics 2006, 4:15 http://www.pophealthmetrics.com/content/4/1/15
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1.6) and for (less than high school) education was 2.1
(95% CI 1.8 – 2.5).
Table 3 shows the frequency of benzodiazepine or similar
sedative-hypnotic use in relation to clinical diagnoses as
well as other chronic illnesses that were recorded during
the CCHS 1.2 interview as self-report (rather than CIDI-
based) items. The highest frequency is in those with CIDI
diagnosed agoraphobia (with or without panic) as well as
those with self-reported schizophrenia. Those with self-
reported epilepsy also reported a high frequency of use.
The lowest frequency of benzodiazepine or similar seda-
tive-hypnotic use occurred in those with substance use
disorders.
Conclusion
The pattern of association between BDZ/SSH use and
demographic variables resembles the pattern reported in
recent French and Italian studies evaluating current use
[17,18], but the actual frequency of use was much lower
in the Canadian sample. In the French study, the fre-
quency of current use was 7.5% [17] and in the Italian
study past week use was 8.6% [18]. European studies
examining use over longer periods have produced only
slightly higher estimates, for example, 9.8% over the past
12-months in the ESEMeD survey [20]. These results are
consistent with the idea that a large proportion of BDZ
users take the medications for long periods.
Lagnaoui et al. [17] were the only previous investigators to
examine the persistence of associations between BDZ/SSH
use and demographic variables after adjustment for the
presence of a mood or anxiety disorder. Their study
included the MINI [21] interview and found, as did the
current study, that these disorders were strongly associ-
ated with the use of BDZ/SSH, but also that inclusion of
these diagnoses in a regression analysis did not eliminate
the effect of demographic variables.
Although the CCHS 1.2 provided an opportunity to
describe the pattern of use of BDZ/SSH, the epidemiolog-
ical determinants of BDZ/SSH were not necessarily com-
prehensively evaluated by the interview used in the study.
Relevant determinants may include psychiatric symptoms
that are not related to these disorders, or disorders that
were not covered by the interview. For example, subjects
with inadequate financial resources may experience more
stress, worry or insomnia than those with higher income.
A higher frequency of use in subjects with such symptoms,
in the absence of a mood or anxiety disorder, could
account for the interaction reported here between diagno-
sis and income category. Some of the differences may be
related to health care utilization patterns, rather than to
clinical or demographic factors. The increased prescribing
for women may, for example, be related to an increased
propensity to seek treatment. Alternatively, demographic
differences in the frequency of use may be due to pre-
scriber characteristics.
BDZ/SSH use was found to occur with a higher frequency
in subjects with anxiety or mood disorders, but not in sub-
jects with substance use disorders. Thus, the frequency of
use seems to be more related to clinical and demographic
factors than to dependence and abuse, at least when these
substance-use disorders are categorized in relation to
DSM-IV criteria.
One weakness of this study was the version of the ATC
classification used. Statistics Canada used a version that
did not include zaleplon, which may therefore have been
coded into an "other" category. As a result, the frequency
of BDZ/SSH use may have been underestimated. However
the size of the residual or unspecified sedative-hypnotic
category was small suggesting that the extent of bias
would not be large. Some older sedative-hypnotics (e.g.
chloral hydrate, barbiturates) were used too infrequently
to be included in the analysis. As the data source was a
Table 3: Frequency (%) of Benzodiazepine and Similar Sedative-Hypnotic Use, by Diagnosis
Diagnosis % 95% C.I.
Any Mood disorder 11.9 10.0 – 13.8
Any Anxiety disorder 11.4 9.4 – 13.4
Any Substance abuse disorder 2.3 1.4 – 3.3
Agoraphobia with panic* 17.5 10.7 – 24.4
Agoraphobia without panic 17.7 9.0 – 26.5
Alcohol Dependence 2.2 1.1 – 3.2
Mania 10.3 6.1 – 14.5
Panic Disorder* 14.2 10.4 – 17.9
Major Depressive Episode 12.3 10.3 – 14.3
Social Phobia 10.0 7.7 – 12.4
Self-reported Epilepsy** 12.4 6.4 – 18.4
Self-reported Schizophrenia** 19.2 11.2 – 27.1
* The diagnoses "agoraphobia with panic" and "panic disorder" are not mutually exclusive.
**The interview included items asking about a diagnosis of these conditions "by a health professional."Publish with BioMed Central    and   every 
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population survey of household residents, homeless and
institutionalized subjects were excluded. The results can-
not be generalized to these other populations.
Certain demographic variables are associated with the use
of BDZ/SSH medications, yet this does not appear to be
easily accounted for by major categories of mental disor-
der. Therefore, focused clinical studies should be con-
ducted in order to identify the causes of these differences,
and to clarify their clinical significance since BDZ/SSH use
in those without obvious indications may also point to
extensive misuse.
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